Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $5.9550 (2.5%) ($5.9550 - $5.9550) on Fri. Sep. 8, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.3% (three month average) | RSI | 47 | Latest Price | $5.9550(2.5%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA declines -0.3% a day on average for past five trading days. | Weekly Trend | IOVA declines -2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IPO(59%) SLV(51%) GDX(45%) GDXJ(42%) INDA(35%) | Factors Impacting IOVA price | IOVA will decline at least -2.15% in a week (0% probabilities). XRT(-38%) XME(-37%) ICLN(-34%) XLP(-32%) XLV(-24%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.15% (StdDev 4.3%) | Hourly BBV | 0.6 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-7.86(-231.99%) | Resistance Level | $6.3 | 5 Day Moving Average | $5.98(-0.42%) | 10 Day Moving Average | $6.04(-1.41%) | 20 Day Moving Average | $6.3(-5.48%) | To recent high | -32.6% | To recent low | 2.5% | Market Cap | $872m | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |